The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.
Ages above 18;
Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He/she or his/her legal representative shall provide written informed consent before participating in the clinical trial.
Clinical symptoms: ischemic chest pain lasting for over 30 minites;
Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit);
Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors;
Previously suffered from myocardial infarction or received coronary artery bypass grafting;
History of severe renal failure, estimated glomerular filtration rate (eGFR) < 30ml/min;
History of severe liver dysfunction, total bilirubin (TBil) > the upper limit of normal, or AST/ALT > 3 times the upper limit of normal, or alkaline phosphatase > 2.5 times the upper limit of normal;
Parallel
Fexofenadine Hydrochloride 60mg bid
DrugFexofenadine hydrochloride 60mg bid treatment for 6 months.
Placebo
Other interventionPlacebo administration for 6 months.
Fexofenadine Hydrochloride 120mg bid
DrugFexofenadine hydrochloride 120mg bid treatment for 6 months.
Late gadolinium enhancement/Left ventricular mass (LGE/LV%)
LGE/LV% will be assessed by CMR
Left ventricular ejection fraction (LVEF)
LVEF will be assessed by CMR
Left ventricular internal dimension in systole/body surface area (LVIDs/BSA%)
LVIDs will be assessed by CMR and BSA will be calculated by height and weight
Left ventricular internal dimension in diastole/body surface area (LVIDd/BSA%)
LVIDd will be assessed by CMR and BSA will be calculated by height and weight
BNP
Analysis of differences of BNP
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
